<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02936037</url>
  </required_header>
  <id_info>
    <org_study_id>MD1003CT2016-01MS-SPI2</org_study_id>
    <nct_id>NCT02936037</nct_id>
  </id_info>
  <brief_title>Effect of MD1003 in Progressive Multiple Sclerosis (SPI2)</brief_title>
  <acronym>SPI2</acronym>
  <official_title>Effect of MD1003 in Progressive Multiple Sclerosis: a Randomized Double Blind Placebo Controlled Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>MedDay Pharmaceuticals SA</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>MedDay Pharmaceuticals SA</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to demonstrate the superiority of MD1003 over placebo in the&#xD;
      disability of patients suffering from progressive multiple sclerosis and especially those&#xD;
      with gait impairment.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Sponsor decision for business purposes&#xD;
  </why_stopped>
  <start_date type="Actual">December 2016</start_date>
  <completion_date type="Actual">April 23, 2020</completion_date>
  <primary_completion_date type="Actual">November 15, 2019</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>PART 1:&#xD;
Total duration of Part 1 is 27 months. The randomized double-blind placebo-controlled period ranges from 15 to 27 months depending upon the randomization date of an individual patient.&#xD;
Once the last month 15 evaluation of the study has been completed, patients will switch to the active drug at the next planned visit. Participants and study personnel will remain blinded as to the original treatment assignment.&#xD;
Maximum duration of double-blind period per patient will be no longer than 27 months.&#xD;
PART 2:&#xD;
At the last evaluation of Part 1 (Visit 11/Month 27) all participants will be offered active treatment in an open label extension for 39 additional months (From V11/M27 to V18/M66).&#xD;
The purpose of the active drug extension is to further define the safety of MD1003.</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Proportion of Patients Improved on Either Expanded Disability Status Scale (EDSS) or Time to Walk 25 Feet (TW25)</measure>
    <time_frame>15 months</time_frame>
    <description>Proportion of patients improved on either Expanded Disability Status Scale (EDSS) or time to walk 25 feet (TW25) :&#xD;
- with decreased EDSS at M12 confirmed at M15 (where decreased EDSS is defined as a decrease of at least 1 point if initial EDSS from 3.5 to 5.5 and of at least 0.5 point if initial EDSS from 6 to 6.5)&#xD;
or&#xD;
- with improved TW25 of at least 20% at Month 12 and Month15&#xD;
compared to the lowest of the two EDSS and TW25* scores among inclusion and randomization visits.&#xD;
*The lowest TW25 value recorded among the four values obtained during the inclusion and randomization visits will be considered as the baseline TW25 value.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Time to 12-Weeks Confirmed EDSS Progression</measure>
    <time_frame>3 to 27 months</time_frame>
    <description>12-weeks EDSS progression is defined by an increase of at least 1 point for baseline EDSS 3.5 to 5.5 and of at least 0.5 point for baseline EDSS 6 to 6.5 with respective confirmation 12 weeks later.&#xD;
Date of 12-weeks confirmed EDSS progression will be the first date of an EDSS progression (as defined above) that is confirmed 12 weeks later.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>CGI-I Score (Clinical Global Impression of Change - Improvement), Evaluated Both by the Patient (SGI) and by the Evaluating Physician (CGI)</measure>
    <time_frame>15 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Change in TW25 Between M0 and M15</measure>
    <time_frame>15 months</time_frame>
  </secondary_outcome>
  <other_outcome>
    <measure>Brain MRI Changes Between M0 and M15</measure>
    <time_frame>15 months</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Remote Monitoring of Ambulation</measure>
    <time_frame>27 months</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>(MSQOL54) &amp; (CAREQOL-MS) Subscores and Composite Scores</measure>
    <time_frame>15 months</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Subscores of the Kurtzke Functional Score</measure>
    <time_frame>15 months</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Symbol Digit Modalities Test (SDMT)</measure>
    <time_frame>15 months</time_frame>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">642</enrollment>
  <condition>Multiple Sclerosis</condition>
  <arm_group>
    <arm_group_label>GROUP 1</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo capsule, 1 capsule tid (morning,noon and evening) for 15 months and up to 27 months.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>GROUP 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>MD1003 capsule, 1 capsule tid (morning,noon and evening) for 15 months and up to 27 months.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>MD1003 100mg capsule</intervention_name>
    <arm_group_label>GROUP 2</arm_group_label>
    <other_name>high dose biotin</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>PLACEBO</intervention_name>
    <description>an inactive substance</description>
    <arm_group_label>GROUP 1</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patient aged 18-65 years old&#xD;
&#xD;
          -  Signed and dated written informed consent form in accordance with local regulations:&#xD;
             having freely given their written informed consent to participate in the study&#xD;
&#xD;
          -  Diagnosis of primary or secondary progressive MS fulfilling revised McDonald criteria&#xD;
             (2010) and Lublin criteria (2014)&#xD;
&#xD;
          -  Documented evidence of clinical disability progression within the 2 years prior to&#xD;
             inclusion, i.e. a) progression of EDSS during the past two years of at least 1 point&#xD;
             sustained for at least 6 months if inclusion EDSS is from 3.5 to 5.5 or at least 0.5&#xD;
             point increase sustained for at least 6 months if inclusion EDSS is from 6 to 6.5 or&#xD;
             b) increase of TW25 by at least 20% in the last two years sustained for at least 6&#xD;
             months or c) other well-documented objective worsening validated by the Adjudication&#xD;
             Committee&#xD;
&#xD;
          -  EDSS at inclusion from 3.5 to 6.5&#xD;
&#xD;
          -  TW25 &lt; 40 seconds at inclusion visit&#xD;
&#xD;
          -  Kurtzke pyramidal functional subscore â‰¥2 defined as &quot;minimal disability: patient&#xD;
             complains of motor-fatigability or reduced performance in strenuous motor tasks (motor&#xD;
             performance grade 1) and/or BMRC grade 4 in one or two muscle groups&quot;&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Clinical evidence of a relapse in 24 months prior to inclusion&#xD;
&#xD;
          -  Treatment with any product containing biotin as single ingredient within six months&#xD;
             prior to inclusion (multivitamin supplementation authorized if biotin &lt; 1mg per day)&#xD;
&#xD;
          -  Concomitant treatment with fampridine at inclusion or in the 30 days prior to&#xD;
             inclusion&#xD;
&#xD;
          -  New immunosuppressive/immunomodulatory drug initiated less than 90 days prior to&#xD;
             inclusion&#xD;
&#xD;
          -  Treatment with botulinum toxin (except for cosmetic purpose) initiated within 6 months&#xD;
             prior to inclusion&#xD;
&#xD;
          -  In-patient rehabilitation program within the 3 months prior to inclusion&#xD;
&#xD;
          -  Pregnancy, breastfeeding or women with childbearing potential without acceptable form&#xD;
             of contraception&#xD;
&#xD;
          -  Men unwilling to use an acceptable form of contraception&#xD;
&#xD;
          -  Any general chronic handicapping/incapacitating disease other than MS&#xD;
&#xD;
          -  Any serious disease necessitating biological follow-up with biological tests using&#xD;
             biotinylated antibodies or substrates&#xD;
&#xD;
          -  Past history of rhabdomyolysis/metabolic myopathy&#xD;
&#xD;
          -  Known fatty acids beta oxidation defect&#xD;
&#xD;
          -  Known hypersensitivity or intolerance to biotin, analogues or excipients, patients&#xD;
             with rare hereditary problems of galactose intolerance, the Lapp lactase deficiency or&#xD;
             glucose-galactose malabsorption&#xD;
&#xD;
          -  Patients with hypersensitivity or any contra-indication to Gadolinium&#xD;
&#xD;
          -  Patients with uncontrolled hepatic disorder, renal or cardiovascular disease, or&#xD;
             cancer&#xD;
&#xD;
          -  Laboratory tests out of normal ranges considered by the investigator as clinically&#xD;
             significant with regards to the study continuation&#xD;
&#xD;
          -  Patients with history or presence of alcohol abuse or drug addiction&#xD;
&#xD;
          -  Untreated or uncontrolled psychiatric disorders, especially suicidal risk assessed by&#xD;
             Columbia-Suicide Severity Rating Scale (C-SSRS)&#xD;
&#xD;
          -  Participation in another research study involving an investigational product (IP) in&#xD;
             the 90 days prior to inclusion, or planned use during the study duration&#xD;
&#xD;
          -  Patients likely to be non-compliant to the study procedures or for whom a long-term&#xD;
             follow-up seems to be difficult to achieve&#xD;
&#xD;
          -  Relapse that occurs between inclusion and randomization visit&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Bruce Cree, MD, PHD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of California, San Francisco</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Frederic Sedel, MD, PHD</last_name>
    <role>Study Director</role>
    <affiliation>Medday Pharmaceuticals</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Barrow Neurology Clinics (BNC)</name>
      <address>
        <city>Phoenix</city>
        <state>Arizona</state>
        <zip>85013</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mayo Clinic Scottsdale</name>
      <address>
        <city>Scottsdale</city>
        <state>Arizona</state>
        <zip>85259</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Jordan Research And Education Institute Of Alta Bates Summit</name>
      <address>
        <city>Berkeley</city>
        <state>California</state>
        <zip>94705</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Neuro-Pain Medical Center</name>
      <address>
        <city>Fresno</city>
        <state>California</state>
        <zip>93710</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Southern California Keck School of Medicine</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90033</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>MS Center of California</name>
      <address>
        <city>Newport Beach</city>
        <state>California</state>
        <zip>92663</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UC Davis Health System</name>
      <address>
        <city>Sacramento</city>
        <state>California</state>
        <zip>95817</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UCSF Multiple Sclerosis Center</name>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <zip>94158</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Colorado Denver</name>
      <address>
        <city>Aurora</city>
        <state>Colorado</state>
        <zip>80045</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Yale New Haven Hospital</name>
      <address>
        <city>North Haven</city>
        <state>Connecticut</state>
        <zip>06473</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Nova Clinical Research, LLC</name>
      <address>
        <city>Bradenton</city>
        <state>Florida</state>
        <zip>34209</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Miami Miller School of Medicine</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33136</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of South Florida - Neurology</name>
      <address>
        <city>Tampa</city>
        <state>Florida</state>
        <zip>33612</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Northwestern University - Feinberg School of Medicine</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60611</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Chicago Medical Center-Duchossois Center for Advanced Medicine (DCAM)</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60637</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Kansas Medical Center</name>
      <address>
        <city>Kansas City</city>
        <state>Kansas</state>
        <zip>66160</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Rowe Neurology Institute</name>
      <address>
        <city>Lenexa</city>
        <state>Kansas</state>
        <zip>66214</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ochsner Health System</name>
      <address>
        <city>New Orleans</city>
        <state>Louisiana</state>
        <zip>70121</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Johns Hopkins Outpatient Center</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21287</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Harvard Medical School - Brigham and Women's Hospital - Center for Neurologic Diseases</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02115</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Wayne State University - Comp Clinic and MS Center</name>
      <address>
        <city>Detroit</city>
        <state>Michigan</state>
        <zip>48201</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Minneapolis Clinic of Neurology, LTD</name>
      <address>
        <city>Golden Valley</city>
        <state>Minnesota</state>
        <zip>55422</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Washington University School of Medicine</name>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <zip>63110</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Holy Name Hospital</name>
      <address>
        <city>Teaneck</city>
        <state>New Jersey</state>
        <zip>07666</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The University of New Mexico - Multiple Sclerosis Specialty Clinic</name>
      <address>
        <city>Albuquerque</city>
        <state>New Mexico</state>
        <zip>87131</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UBMD Neurology</name>
      <address>
        <city>Buffalo</city>
        <state>New York</state>
        <zip>14203</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mount Sinai School of Medicine - Corinne Goldsmith Dickinson Center for MS</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10029</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Columbia University Medical Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10032</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Rochester Medical Center</name>
      <address>
        <city>Rochester</city>
        <state>New York</state>
        <zip>14642</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>State University of New York (SUNY)</name>
      <address>
        <city>Stony Brook</city>
        <state>New York</state>
        <zip>11794</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Raleigh Neurology Associates, P.A.</name>
      <address>
        <city>Raleigh</city>
        <state>North Carolina</state>
        <zip>27607</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cleveland Clinic Mellen Center for MS</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44195</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Providence Multiple Sclerosis Center</name>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <zip>97225</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Thomas Jefferson University</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19107</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>New Orleans Center for Clinical Research</name>
      <address>
        <city>Knoxville</city>
        <state>Tennessee</state>
        <zip>37920</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Vanderbilt Comprehensive Multiple Sclerosis Center</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37215</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Texas Southwestern Medical Center</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75390</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Central Texas Neurology Consultants</name>
      <address>
        <city>Round Rock</city>
        <state>Texas</state>
        <zip>78681</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Virginia Health System</name>
      <address>
        <city>Charlottesville</city>
        <state>Virginia</state>
        <zip>22903</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Virginia Mason Medical Center</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98101</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Brain and Mind Centre/University of Sydney</name>
      <address>
        <city>Sydney</city>
        <state>New South Wales</state>
        <zip>2050</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Austin Hospital</name>
      <address>
        <city>Heidelberg</city>
        <state>Victoria</state>
        <zip>3084</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Royal Melbourne Hospital</name>
      <address>
        <city>Parkville</city>
        <state>Victoria</state>
        <zip>3050</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UZ Antwerpen</name>
      <address>
        <city>Edegem</city>
        <state>Antwerpen</state>
        <zip>2650</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Jessa Ziekenhuis - Campus Virga Jesse</name>
      <address>
        <city>Hasselt</city>
        <state>Limburg</state>
        <zip>3500</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UZ Gent</name>
      <address>
        <city>Halle</city>
        <state>Oost-Vlaanderen</state>
        <zip>9000</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Burnaby Hospital</name>
      <address>
        <city>Burnaby</city>
        <state>British Columbia</state>
        <zip>V5G 2X6</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Vancouver Hospital and Health Sciences Centre</name>
      <address>
        <city>Vancouver</city>
        <state>British Columbia</state>
        <zip>V6T 2B5</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>HÃ´pital universitaire Dr George L-Dumont university Hospital</name>
      <address>
        <city>Moncton</city>
        <state>New Brunswick</state>
        <zip>E1C 2Z3</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Nova Scotia Rehabilitation Center</name>
      <address>
        <city>Halifax</city>
        <state>Nova Scotia</state>
        <zip>B3H 4K4</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ottawa Hospital General Campus</name>
      <address>
        <city>Ottawa</city>
        <state>Ontario</state>
        <zip>ON K1H 8L6</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St. Michael's Hospital</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M5B 1W8</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Montreal Neurologic Institute</name>
      <address>
        <city>Montreal</city>
        <state>Quebec</state>
        <zip>H3A 2B4</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hopital de Notre Dame</name>
      <address>
        <city>MontrÃ©al</city>
        <state>Quebec</state>
        <zip>H2L 4M1</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>doc. MUDr. Radomir Talab, CSc., neurologie</name>
      <address>
        <city>Hradec KrÃ¡lovÃ©</city>
        <zip>500 03</zip>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Nemocnice Jihlava</name>
      <address>
        <city>Jihlava</city>
        <zip>586 33</zip>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Vseobecna fakultni nemocnice v Praze</name>
      <address>
        <city>Praha</city>
        <zip>128 21</zip>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Fakultni nemocnice v Motole</name>
      <address>
        <city>Praha</city>
        <zip>150 06</zip>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Nemocnice Teplice</name>
      <address>
        <city>Teplice</city>
        <zip>415 29</zip>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UniversitÃ¤tsklinikum Leipzig A.Ã¶.R. - Klinik und Poliklinik</name>
      <address>
        <city>Leipzig</city>
        <state>Sachsen</state>
        <zip>04103</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Fachkrankenhaus Hubertusburg</name>
      <address>
        <city>Wermsdorf</city>
        <state>Sachsen</state>
        <zip>04779</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Caritas Krankenhaus</name>
      <address>
        <city>Bad Mergentheim</city>
        <zip>97980</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CharitÃ© - UniversitÃ¤tsmedizin Berlin / NeuroCure Clinical Research Center</name>
      <address>
        <city>Berlin</city>
        <zip>10117</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Heinrich-Heine-UniversitÃ¤t DÃ¼sseldorf</name>
      <address>
        <city>Dusseldorf</city>
        <zip>40225</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Neuro Centrum Science GmbH</name>
      <address>
        <city>Erbach</city>
        <zip>64711</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>MultipEL Studies Institut fÃ¼r klinische Studien GbR</name>
      <address>
        <city>Hamburg</city>
        <zip>22179</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ludwig-Maximilians UniversitÃ¤t MÃ¼nchen</name>
      <address>
        <city>MÃ¼nchen</city>
        <zip>81377</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Neuropoint GmbH</name>
      <address>
        <city>Ulm</city>
        <zip>89073</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Poliklinik fÃ¼r Neurologie UniversitÃ¤tsklinikum Ulm</name>
      <address>
        <city>Ulm</city>
        <zip>89081</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Valeomed Kft</name>
      <address>
        <city>Esztergom</city>
        <zip>2500</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ospedale San Raffaele, IRCCS</name>
      <address>
        <city>Milano</city>
        <zip>20132</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>AO S.Andrea, UniversitÃ  degli Studi di Roma La Sapienza</name>
      <address>
        <city>Roma</city>
        <zip>00189</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Nasz Lekarz OÅ›rodek BadaÅ„ Klinicznych</name>
      <address>
        <city>Bydgoszcz</city>
        <zip>85-794</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>COPERNICUS PL sp z o.o.,Szpital im. M.Kopernika OddziaÅ‚ Neurologiczny</name>
      <address>
        <city>Gdansk</city>
        <zip>80-803</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Twoja Przychodnia Centrum Medyczne Nowa Sol</name>
      <address>
        <city>Nowa Sol</city>
        <zip>67-100</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centrum Medyczne Pratia Warszawa</name>
      <address>
        <city>Warszawa</city>
        <zip>01-868</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Santa Caterina</name>
      <address>
        <city>Salt</city>
        <state>Girona</state>
        <zip>17190</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hostipal Universitario QuirÃ³nsalud Madrid</name>
      <address>
        <city>Pozuelo de AlarcÃ³n</city>
        <state>Madrid</state>
        <zip>28223</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Servicio de NeurologÃ­a Hospital Vithas Nisa Aljarafe</name>
      <address>
        <city>Castilleja de la Cuesta</city>
        <state>Sevilla</state>
        <zip>41950</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital del Mar Servicio de NeurologÃ­a</name>
      <address>
        <city>Barcelona</city>
        <zip>08003</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitari Vall d'Hebron</name>
      <address>
        <city>Barcelona</city>
        <zip>08035</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital ClÃ­nico San Carlos</name>
      <address>
        <city>Madrid</city>
        <zip>28040</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Regional Universitario de MÃ¡laga</name>
      <address>
        <city>Malaga</city>
        <zip>29010</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sahlgrenska Universitetssjukhus - MS Center forskningsenheten</name>
      <address>
        <city>GÃ¶teborg</city>
        <zip>413 45</zip>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Karolinska University Hospital - Neurologmottagningen</name>
      <address>
        <city>Stockholm</city>
        <zip>171 76</zip>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ondokuz Mayis University Medical Faculty</name>
      <address>
        <city>Samsun</city>
        <zip>55139</zip>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The University of Edinburgh</name>
      <address>
        <city>Edinburgh</city>
        <zip>EH16 4SB</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Institute of Neurological Sciences</name>
      <address>
        <city>Glasgow</city>
        <zip>G51 4TF</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Barts And The London School Of Medicine And Dentistry Institute</name>
      <address>
        <city>London</city>
        <zip>E1 2AT</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University College London Institute of Neurology / National Hospital for Neurology &amp; Neurosurgery</name>
      <address>
        <city>London</city>
        <zip>WC1N 3BG</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Tyne Hospitals NHS Foundation</name>
      <address>
        <city>Newcastle upon Tyne</city>
        <zip>NE1 4LP</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Salford Royal Hospital</name>
      <address>
        <city>Salford</city>
        <zip>M6 8HD</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Australia</country>
    <country>Belgium</country>
    <country>Canada</country>
    <country>Czechia</country>
    <country>Germany</country>
    <country>Hungary</country>
    <country>Italy</country>
    <country>Poland</country>
    <country>Spain</country>
    <country>Sweden</country>
    <country>Turkey</country>
    <country>United Kingdom</country>
    <country>United States</country>
  </location_countries>
  <removed_countries>
    <country>Czech Republic</country>
    <country>Netherlands</country>
  </removed_countries>
  <link>
    <url>http://www.medday-pharma.com</url>
    <description>Sponsor</description>
  </link>
  <link>
    <url>http://www.spi2study.com</url>
    <description>clinical trial dedicated website</description>
  </link>
  <verification_date>October 2020</verification_date>
  <study_first_submitted>October 14, 2016</study_first_submitted>
  <study_first_submitted_qc>October 14, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 18, 2016</study_first_posted>
  <results_first_submitted>October 29, 2020</results_first_submitted>
  <results_first_submitted_qc>October 29, 2020</results_first_submitted_qc>
  <results_first_posted type="Actual">November 23, 2020</results_first_posted>
  <last_update_submitted>October 29, 2020</last_update_submitted>
  <last_update_submitted_qc>October 29, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">November 23, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>progressive multiple sclerosis</keyword>
  <keyword>MS</keyword>
  <keyword>EDSS</keyword>
  <keyword>TW25</keyword>
  <keyword>multiple sclerosis</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Multiple Sclerosis</mesh_term>
    <mesh_term>Multiple Sclerosis, Chronic Progressive</mesh_term>
    <mesh_term>Sclerosis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Biotin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>November 12, 2018</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/37/NCT02936037/Prot_000.pdf</document_url>
    </provided_document>
    <provided_document>
      <document_type>Statistical Analysis Plan</document_type>
      <document_has_protocol>No</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>February 10, 2020</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/37/NCT02936037/SAP_001.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Placebo</title>
          <description>Placebo capsule, 1 capsule tid (morning,noon and evening) for 15 months and up to 27 months.&#xD;
PLACEBO: an inactive substance</description>
        </group>
        <group group_id="P2">
          <title>MD1003</title>
          <description>MD1003 capsule, 1 capsule tid (morning,noon and evening) for 15 months and up to 27 months.&#xD;
MD1003 100mg capsule</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Double-Blind Treatment Period</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="316"/>
                <participants group_id="P2" count="326"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="267"/>
                <participants group_id="P2" count="261"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="49"/>
                <participants group_id="P2" count="65"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="4"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Suicidal risk, etc.</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="8"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lack of Efficacy</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="12"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Death</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="11"/>
                <participants group_id="P2" count="11"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="31"/>
                <participants group_id="P2" count="28"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
        <period>
          <title>Open Label Extension</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="528"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="518"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="10"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Other</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="4"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Placebo</title>
          <description>Placebo capsule, 1 capsule tid (morning,noon and evening) for 15 months and up to 27 months.&#xD;
PLACEBO: an inactive substance</description>
        </group>
        <group group_id="B2">
          <title>MD1003</title>
          <description>MD1003 capsule, 1 capsule tid (morning,noon and evening) for 15 months and up to 27 months.&#xD;
MD1003 100mg capsule</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="316"/>
            <count group_id="B2" value="326"/>
            <count group_id="B3" value="642"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="52.8" spread="7.60"/>
                    <measurement group_id="B2" value="52.6" spread="7.79"/>
                    <measurement group_id="B3" value="52.7" spread="7.70"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="170"/>
                    <measurement group_id="B2" value="175"/>
                    <measurement group_id="B3" value="345"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="146"/>
                    <measurement group_id="B2" value="151"/>
                    <measurement group_id="B3" value="297"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="9"/>
                    <measurement group_id="B2" value="12"/>
                    <measurement group_id="B3" value="21"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="293"/>
                    <measurement group_id="B2" value="302"/>
                    <measurement group_id="B3" value="595"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="14"/>
                    <measurement group_id="B2" value="12"/>
                    <measurement group_id="B3" value="26"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="5"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="13"/>
                    <measurement group_id="B2" value="8"/>
                    <measurement group_id="B3" value="21"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="291"/>
                    <measurement group_id="B2" value="306"/>
                    <measurement group_id="B3" value="597"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="9"/>
                    <measurement group_id="B2" value="10"/>
                    <measurement group_id="B3" value="19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Hungary</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="109"/>
                    <measurement group_id="B2" value="109"/>
                    <measurement group_id="B3" value="218"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Czechia</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="26"/>
                    <measurement group_id="B2" value="31"/>
                    <measurement group_id="B3" value="57"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>United Kingdom</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="31"/>
                    <measurement group_id="B2" value="30"/>
                    <measurement group_id="B3" value="61"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Spain</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="30"/>
                    <measurement group_id="B2" value="31"/>
                    <measurement group_id="B3" value="61"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Canada</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="35"/>
                    <measurement group_id="B2" value="37"/>
                    <measurement group_id="B3" value="72"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Sweden</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="9"/>
                    <measurement group_id="B2" value="9"/>
                    <measurement group_id="B3" value="18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Turkey</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Belgium</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="7"/>
                    <measurement group_id="B3" value="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Poland</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="11"/>
                    <measurement group_id="B2" value="12"/>
                    <measurement group_id="B3" value="23"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Italy</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                    <measurement group_id="B2" value="7"/>
                    <measurement group_id="B3" value="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Australia</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                    <measurement group_id="B2" value="8"/>
                    <measurement group_id="B3" value="14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Germany</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="48"/>
                    <measurement group_id="B2" value="42"/>
                    <measurement group_id="B3" value="90"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Proportion of Patients Improved on Either Expanded Disability Status Scale (EDSS) or Time to Walk 25 Feet (TW25)</title>
        <description>Proportion of patients improved on either Expanded Disability Status Scale (EDSS) or time to walk 25 feet (TW25) :&#xD;
- with decreased EDSS at M12 confirmed at M15 (where decreased EDSS is defined as a decrease of at least 1 point if initial EDSS from 3.5 to 5.5 and of at least 0.5 point if initial EDSS from 6 to 6.5)&#xD;
or&#xD;
- with improved TW25 of at least 20% at Month 12 and Month15&#xD;
compared to the lowest of the two EDSS and TW25* scores among inclusion and randomization visits.&#xD;
*The lowest TW25 value recorded among the four values obtained during the inclusion and randomization visits will be considered as the baseline TW25 value.</description>
        <time_frame>15 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Placebo capsule, 1 capsule tid (morning,noon and evening) for 15 months and up to 27 months.&#xD;
PLACEBO: an inactive substance</description>
          </group>
          <group group_id="O2">
            <title>MD1003</title>
            <description>MD1003 capsule, 1 capsule tid (morning,noon and evening) for 15 months and up to 27 months.&#xD;
MD1003 100mg capsule</description>
          </group>
        </group_list>
        <measure>
          <title>Proportion of Patients Improved on Either Expanded Disability Status Scale (EDSS) or Time to Walk 25 Feet (TW25)</title>
          <description>Proportion of patients improved on either Expanded Disability Status Scale (EDSS) or time to walk 25 feet (TW25) :&#xD;
- with decreased EDSS at M12 confirmed at M15 (where decreased EDSS is defined as a decrease of at least 1 point if initial EDSS from 3.5 to 5.5 and of at least 0.5 point if initial EDSS from 6 to 6.5)&#xD;
or&#xD;
- with improved TW25 of at least 20% at Month 12 and Month15&#xD;
compared to the lowest of the two EDSS and TW25* scores among inclusion and randomization visits.&#xD;
*The lowest TW25 value recorded among the four values obtained during the inclusion and randomization visits will be considered as the baseline TW25 value.</description>
          <units>percent</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="316"/>
                <count group_id="O2" value="326"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9.2"/>
                    <measurement group_id="O2" value="12.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Time to 12-Weeks Confirmed EDSS Progression</title>
        <description>12-weeks EDSS progression is defined by an increase of at least 1 point for baseline EDSS 3.5 to 5.5 and of at least 0.5 point for baseline EDSS 6 to 6.5 with respective confirmation 12 weeks later.&#xD;
Date of 12-weeks confirmed EDSS progression will be the first date of an EDSS progression (as defined above) that is confirmed 12 weeks later.</description>
        <time_frame>3 to 27 months</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>CGI-I Score (Clinical Global Impression of Change - Improvement), Evaluated Both by the Patient (SGI) and by the Evaluating Physician (CGI)</title>
        <time_frame>15 months</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Change in TW25 Between M0 and M15</title>
        <time_frame>15 months</time_frame>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Brain MRI Changes Between M0 and M15</title>
        <time_frame>15 months</time_frame>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Remote Monitoring of Ambulation</title>
        <time_frame>27 months</time_frame>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>(MSQOL54) &amp; (CAREQOL-MS) Subscores and Composite Scores</title>
        <time_frame>15 months</time_frame>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Subscores of the Kurtzke Functional Score</title>
        <time_frame>15 months</time_frame>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Symbol Digit Modalities Test (SDMT)</title>
        <time_frame>15 months</time_frame>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Adverse events were collected over 27 months for the double-blind period, and was to be collected for 39 months in open-label extension before premature termination of the study.</time_frame>
      <group_list>
        <group group_id="E1">
          <title>GROUP 1</title>
          <description>Placebo capsule, 1 capsule tid (morning,noon and evening) for 15 months and up to 27 months.&#xD;
PLACEBO: an inactive substance</description>
        </group>
        <group group_id="E2">
          <title>GROUP 2</title>
          <description>MD1003 capsule, 1 capsule tid (morning,noon and evening) for 15 months and up to 27 months.&#xD;
MD1003 100mg capsule</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="311"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="331"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="82" subjects_at_risk="311"/>
                <counts group_id="E2" subjects_affected="87" subjects_at_risk="331"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Leukopenia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="311"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="331"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Atrial fibrillation</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="311"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="331"/>
              </event>
              <event>
                <sub_title>Acute myocardial infarction</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="311"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="331"/>
              </event>
              <event>
                <sub_title>Cardiac failure</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="311"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="331"/>
              </event>
              <event>
                <sub_title>Myocardial infarction</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="311"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="331"/>
              </event>
              <event>
                <sub_title>Silent myocardial infarction</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="311"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="331"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Congenital, familial and genetic disorders</title>
            <event_list>
              <event>
                <sub_title>Factor V Leiden mutation</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="311"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="331"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Ear and labyrinth disorders</title>
            <event_list>
              <event>
                <sub_title>Vertigo</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="311"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="331"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Eye pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="311"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="331"/>
              </event>
              <event>
                <sub_title>Eyelid ptosis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="311"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="331"/>
              </event>
              <event>
                <sub_title>Vision blurred</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="311"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="331"/>
              </event>
              <event>
                <sub_title>Vitreous haemorrhage</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="311"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="331"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="311"/>
                <counts group_id="E2" events="3" subjects_affected="1" subjects_at_risk="331"/>
              </event>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="311"/>
                <counts group_id="E2" events="2" subjects_affected="1" subjects_at_risk="331"/>
              </event>
              <event>
                <sub_title>Crohn's disease</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="311"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="331"/>
              </event>
              <event>
                <sub_title>Diaphragmatic hernia, obstructive</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="311"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="331"/>
              </event>
              <event>
                <sub_title>Gastrointestinal perforation</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="311"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="331"/>
              </event>
              <event>
                <sub_title>Haematochezia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="311"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="331"/>
              </event>
              <event>
                <sub_title>Oesophagitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="311"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="331"/>
              </event>
              <event>
                <sub_title>Rectal prolapse</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="311"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="331"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="311"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="331"/>
              </event>
              <event>
                <sub_title>General physical health deterioration</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="311"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="331"/>
              </event>
              <event>
                <sub_title>Gait disturbance</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="311"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="331"/>
              </event>
              <event>
                <sub_title>Pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="311"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="331"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Cholecystitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="311"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="331"/>
              </event>
              <event>
                <sub_title>Cholelithiasis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="311"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="331"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="311"/>
                <counts group_id="E2" events="3" subjects_affected="2" subjects_at_risk="331"/>
              </event>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="311"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="331"/>
              </event>
              <event>
                <sub_title>Urosepsis</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="311"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="331"/>
              </event>
              <event>
                <sub_title>Bacterial infection</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="311"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="331"/>
              </event>
              <event>
                <sub_title>Bronchitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="311"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="331"/>
              </event>
              <event>
                <sub_title>Appendicitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="311"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="331"/>
              </event>
              <event>
                <sub_title>Bacteraemia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="311"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="331"/>
              </event>
              <event>
                <sub_title>Clostridium difficile colitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="311"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="331"/>
              </event>
              <event>
                <sub_title>Clostridium difficile infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="311"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="331"/>
              </event>
              <event>
                <sub_title>Epididymitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="311"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="331"/>
              </event>
              <event>
                <sub_title>Escherichia urinary tract infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="311"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="331"/>
              </event>
              <event>
                <sub_title>Gastroenteritis norovirus</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="311"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="331"/>
              </event>
              <event>
                <sub_title>Haemorrhagic pneumonia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="311"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="331"/>
              </event>
              <event>
                <sub_title>Human anaplasmosis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="311"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="331"/>
              </event>
              <event>
                <sub_title>Incision site infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="311"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="331"/>
              </event>
              <event>
                <sub_title>Lower respiratory tract infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="311"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="331"/>
              </event>
              <event>
                <sub_title>Lung abscess</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="311"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="331"/>
              </event>
              <event>
                <sub_title>Lyme disease</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="311"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="331"/>
              </event>
              <event>
                <sub_title>Septic shock</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="311"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="331"/>
              </event>
              <event>
                <sub_title>Viral infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="311"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="331"/>
              </event>
              <event>
                <sub_title>Viral upper respiratory tract infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="311"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="331"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Femoral neck fracture</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="311"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="331"/>
              </event>
              <event>
                <sub_title>Ankle fracture</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="311"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="331"/>
              </event>
              <event>
                <sub_title>Hip fracture</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="311"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="331"/>
              </event>
              <event>
                <sub_title>Tibia fracture</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="311"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="331"/>
              </event>
              <event>
                <sub_title>Contusion</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="311"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="331"/>
              </event>
              <event>
                <sub_title>Femur fracture</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="311"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="331"/>
              </event>
              <event>
                <sub_title>Fibula fracture</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="311"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="331"/>
              </event>
              <event>
                <sub_title>Heat stroke</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="311"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="331"/>
              </event>
              <event>
                <sub_title>Humerus fracture</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="311"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="331"/>
              </event>
              <event>
                <sub_title>Lumbar vertebral fracture</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="311"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="331"/>
              </event>
              <event>
                <sub_title>Spinal compression fracture</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="311"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="331"/>
              </event>
              <event>
                <sub_title>Spinal fracture</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="311"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="331"/>
              </event>
              <event>
                <sub_title>Sunburn</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="311"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="331"/>
              </event>
              <event>
                <sub_title>Upper limb fracture</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="311"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="331"/>
              </event>
              <event>
                <sub_title>Wrist fracture</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="311"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="331"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Dehydration</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="311"/>
                <counts group_id="E2" events="2" subjects_affected="1" subjects_at_risk="331"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Muscular weakness</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="311"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="331"/>
              </event>
              <event>
                <sub_title>Pain in extremity</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="311"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="331"/>
              </event>
              <event>
                <sub_title>Intervertebral disc protrusion</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="311"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="331"/>
              </event>
              <event>
                <sub_title>Joint stiffness</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="311"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="331"/>
              </event>
              <event>
                <sub_title>Muscle spasms</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="311"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="331"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Cervix carcinoma</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="311"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="331"/>
              </event>
              <event>
                <sub_title>Cystadenocarcinoma ovary</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="311"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="331"/>
              </event>
              <event>
                <sub_title>Intraductal proliferative breast lesion</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="311"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="331"/>
              </event>
              <event>
                <sub_title>Ovarian cancer</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="311"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="331"/>
              </event>
              <event>
                <sub_title>Ovarian cancer metastatic</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="311"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="331"/>
              </event>
              <event>
                <sub_title>Pituitary tumour benign</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="311"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="331"/>
              </event>
              <event>
                <sub_title>Rectal adenoma</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="311"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="331"/>
              </event>
              <event>
                <sub_title>Testis cancer</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="311"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="331"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Multiple sclerosis relapse</sub_title>
                <counts group_id="E1" events="37" subjects_affected="31" subjects_at_risk="311"/>
                <counts group_id="E2" events="36" subjects_affected="29" subjects_at_risk="331"/>
              </event>
              <event>
                <sub_title>Multiple sclerosis</sub_title>
                <counts group_id="E1" events="7" subjects_affected="6" subjects_at_risk="311"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="331"/>
              </event>
              <event>
                <sub_title>Trigeminal neuralgia</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="311"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="331"/>
              </event>
              <event>
                <sub_title>Muscle spasticity</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="311"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="331"/>
              </event>
              <event>
                <sub_title>Uhthoff's phenomenon</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="311"/>
                <counts group_id="E2" events="2" subjects_affected="1" subjects_at_risk="331"/>
              </event>
              <event>
                <sub_title>Hypoaesthesia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="311"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="331"/>
              </event>
              <event>
                <sub_title>Sensory Loss</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="311"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="331"/>
              </event>
              <event>
                <sub_title>Aphasia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="311"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="331"/>
              </event>
              <event>
                <sub_title>Cataplexy</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="311"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="331"/>
              </event>
              <event>
                <sub_title>Cerebral infarction</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="311"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="331"/>
              </event>
              <event>
                <sub_title>Cerebrovascular accident</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="311"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="331"/>
              </event>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="311"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="331"/>
              </event>
              <event>
                <sub_title>Encephalopathy</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="311"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="331"/>
              </event>
              <event>
                <sub_title>Facial paralysis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="311"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="331"/>
              </event>
              <event>
                <sub_title>Facial spasm</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="311"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="331"/>
              </event>
              <event>
                <sub_title>Ischaemic stroke</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="311"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="331"/>
              </event>
              <event>
                <sub_title>Narcolepsy</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="311"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="331"/>
              </event>
              <event>
                <sub_title>Neuralgia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="311"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="331"/>
              </event>
              <event>
                <sub_title>Normal pressure hydrocephalus</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="311"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="331"/>
              </event>
              <event>
                <sub_title>Optic neuritis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="311"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="331"/>
              </event>
              <event>
                <sub_title>Paraparesis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="311"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="331"/>
              </event>
              <event>
                <sub_title>Pyramidal tract syndrome</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="311"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="331"/>
              </event>
              <event>
                <sub_title>Sciatica</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="311"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="331"/>
              </event>
              <event>
                <sub_title>Transverse sinus thrombosis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="311"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="331"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Product Issues</title>
            <event_list>
              <event>
                <sub_title>Device failure</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="311"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="331"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Depression</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="311"/>
                <counts group_id="E2" events="2" subjects_affected="1" subjects_at_risk="331"/>
              </event>
              <event>
                <sub_title>Confusional state</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="311"/>
                <counts group_id="E2" events="2" subjects_affected="1" subjects_at_risk="331"/>
              </event>
              <event>
                <sub_title>Suicide attempt</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="311"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="331"/>
              </event>
              <event>
                <sub_title>Bipolar I disorder</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="311"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="331"/>
              </event>
              <event>
                <sub_title>Bipolar disorder</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="311"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="331"/>
              </event>
              <event>
                <sub_title>Breathing-related sleeping disorder</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="311"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="331"/>
              </event>
              <event>
                <sub_title>Disorientation</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="311"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="331"/>
              </event>
              <event>
                <sub_title>Substance-induced psychotic disorder</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="311"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="331"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Nephrolithiasis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="311"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="331"/>
              </event>
              <event>
                <sub_title>Pelvi-ureteric obstruction</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="311"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="331"/>
              </event>
              <event>
                <sub_title>Ureteric stenosis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="311"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="331"/>
              </event>
              <event>
                <sub_title>Ureterolithiasis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="311"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="331"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Cervical dysplasia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="311"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="331"/>
              </event>
              <event>
                <sub_title>Ovarian cyst</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="311"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="331"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Pulmonary embolism</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="311"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="331"/>
              </event>
              <event>
                <sub_title>Chronic obstructive pulmonary disease</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="311"/>
                <counts group_id="E2" events="3" subjects_affected="2" subjects_at_risk="331"/>
              </event>
              <event>
                <sub_title>Asthma</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="311"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="331"/>
              </event>
              <event>
                <sub_title>Pleural effusion</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="311"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="331"/>
              </event>
              <event>
                <sub_title>Pulmonary mass</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="311"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="331"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Surgical and medical procedures</title>
            <event_list>
              <event>
                <sub_title>Elective procedure</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="311"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="331"/>
              </event>
              <event>
                <sub_title>Neurological rehabilitation</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="311"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="331"/>
              </event>
              <event>
                <sub_title>Gastric banding reversal</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="311"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="331"/>
              </event>
              <event>
                <sub_title>Rehabilitation therapy</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="311"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="331"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Deep vein thrombosis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="311"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="331"/>
              </event>
              <event>
                <sub_title>Peripheral arterial occlusive disease</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="311"/>
                <counts group_id="E2" events="2" subjects_affected="1" subjects_at_risk="331"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="264" subjects_at_risk="311"/>
                <counts group_id="E2" subjects_affected="277" subjects_at_risk="331"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" events="16" subjects_affected="16" subjects_at_risk="311"/>
                <counts group_id="E2" events="19" subjects_affected="18" subjects_at_risk="331"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" events="28" subjects_affected="26" subjects_at_risk="311"/>
                <counts group_id="E2" events="26" subjects_affected="24" subjects_at_risk="331"/>
              </event>
              <event>
                <sub_title>Gait disturbance</sub_title>
                <counts group_id="E1" events="21" subjects_affected="17" subjects_at_risk="311"/>
                <counts group_id="E2" events="28" subjects_affected="22" subjects_at_risk="331"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" events="94" subjects_affected="50" subjects_at_risk="311"/>
                <counts group_id="E2" events="74" subjects_affected="48" subjects_at_risk="331"/>
              </event>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" events="76" subjects_affected="58" subjects_at_risk="311"/>
                <counts group_id="E2" events="53" subjects_affected="39" subjects_at_risk="331"/>
              </event>
              <event>
                <sub_title>Upper respiratory tract infection</sub_title>
                <counts group_id="E1" events="34" subjects_affected="27" subjects_at_risk="311"/>
                <counts group_id="E2" events="33" subjects_affected="25" subjects_at_risk="331"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Fall</sub_title>
                <counts group_id="E1" events="60" subjects_affected="37" subjects_at_risk="311"/>
                <counts group_id="E2" events="84" subjects_affected="44" subjects_at_risk="331"/>
              </event>
              <event>
                <sub_title>Contusion</sub_title>
                <counts group_id="E1" events="26" subjects_affected="23" subjects_at_risk="311"/>
                <counts group_id="E2" events="20" subjects_affected="13" subjects_at_risk="331"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Laboratory test interference</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="311"/>
                <counts group_id="E2" events="28" subjects_affected="25" subjects_at_risk="331"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Arthralgia</sub_title>
                <counts group_id="E1" events="31" subjects_affected="26" subjects_at_risk="311"/>
                <counts group_id="E2" events="29" subjects_affected="25" subjects_at_risk="331"/>
              </event>
              <event>
                <sub_title>Muscular weakness</sub_title>
                <counts group_id="E1" events="33" subjects_affected="24" subjects_at_risk="311"/>
                <counts group_id="E2" events="27" subjects_affected="20" subjects_at_risk="331"/>
              </event>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" events="21" subjects_affected="21" subjects_at_risk="311"/>
                <counts group_id="E2" events="25" subjects_affected="19" subjects_at_risk="331"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Multiple sclerosis relapse</sub_title>
                <counts group_id="E1" events="37" subjects_affected="31" subjects_at_risk="311"/>
                <counts group_id="E2" events="36" subjects_affected="29" subjects_at_risk="331"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Depression</sub_title>
                <counts group_id="E1" events="12" subjects_affected="12" subjects_at_risk="311"/>
                <counts group_id="E2" events="23" subjects_affected="17" subjects_at_risk="331"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr FrÃ©dÃ©ric SEDEL, Chief Scientific Officer and Co-founder</name_or_title>
      <organization>MedDay Pharmaceuticals</organization>
      <phone>+33180401440</phone>
      <email>frederic.sedel@medday-pharma.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

